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Abstract 
Objective: The overall purpose of the study was to demonstrate applicability of the 
DAKO dual-color chromogenic in situ hybridization (CISH) assay (DAKO Denmark, 
Glostrup) with respect to fluorescence in situ hybridization (FISH) probes MYC-C.  
Methods: MYC gene amplification by FISH and DAKO dual-color CISH 
Results: The study showed that the dual-color CISH assay can convert Texas red and 
fluorescein isothiocyanate (FITC) signals into chromogenic signals. The dual –color 
CISH assay was performed on 40 cases of prostate cancer. Amplification was identified 
in 12 of 40 (30%) tumors. No amplification was seen in 28 of 40 (70%) tumors. FISH 
data were available in total of 40 tumors. All tumors showed concordant results between 
dual-color CISH and FISH for classifying a tumor as MYC amplified or not amplified.  
Conclusions: We conclude that dual-color DAKO CISH assay is an accurate method for 
determining MYC gene amplification with added advantages that make it a more 
practically useful method. 
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INTRODUCTION 
Prostate cancer (PCa) is a common malignancy in men 
in Western countries, has the characteristics of a 
heterogeneous damage with multiple risk factors [1]. 
The increase in the incidence of PCa in the last twenty 
years has assumed almost epidemic proportions 
because this neoplasm is the most frequently diagnosed 
solid tumor and that in our country is the second 
leading cause of death oncology [2]. There is consistent 
evidence that PCa deaths have decreased over the last 
decade, most likely associated with the extensive use of 
prostate specific antigen (PSA) in the early diagnosis of 
the disease [3].The 8q24.21 region, where MYC is 
located, is contained within a region that is commonly 
amplified in prostate cancer, especially in advanced and 
recurrent disease [4]. By chromosome microdissection, 
8q24 amplification was first identified in 2 prostate 
cancer cases [4]. To verify this, fluorescence in situ 
hybridization (FISH) was carried out on 44 
prostatectomy samples, and the amplification was 
present in only 9 % of the total cases studied but 75 % 
of advanced cases. Accordingly, in the study of patients 
with recurrent disease, comparative genomic 
hybridization and FISH analysis showed 8q24 
amplification in 8 of 9 cases [4]. 
Because the amplification of the 8q24 region is 
predominantly observed in late-stage/aggressive 
tumors, it has been widely held that MYC is involved 
in disease progression [4]. Interestingly, the 
amplification of MYC is generally on the order of a 
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few fold; high-level amplifications, such as those seen 
with MYC-N in a subset of neuroblastomas, are 
virtually never seen in prostate cancer. 
Fluorescence in situ hybridization (FISH) has achieved 
widespread use for a range of gene copy number 
detection probes and translocation probes. It is 
considered a very accurate and sensitive method, e.g., 
the College of American Pathologists has published 
that FISH is to be regarded as “gold standard” for 
HER2 testing [5]. However, the FISH method is 
perceived as having some limitations. The evaluation of 
tumor morphologic features through FISH may be 
difficult, and the method requires a fluorescence 
microscope, which is costly and not readily available in 
all pathology laboratories.  
Furthermore, the fluorescence signals fade relatively 
quickly, which makes archiving of the slides difficult. 
These limitations can be overcome by chromogenic in 
situ hybridization (CISH), which converts the 
fluorescence signals into chromogenic precipitates, and 
can visualize FISH-labeled probes along with the 
morphologic features using a brightfield microscope 
[6]. 
Hoff et.al [6] developed a dual-color CISH assay in 
which the green fluorescein isothiocyanate (FITC) 
FISH signals are converted into red chromogenic 
precipitates [7,8].  
The purpose of this study was demonstrate the general 
use of the DAKO dual-color CISH assay (DAKO 
Denmark, Glostrup) by applying it to gene copy 
detection probe as MYC-C. 
MATERIAL AND METHODS 
Case Selection 
Archival formalin-fixed paraffin-embedded tissues 
from 40 prostate cancers were randomly selected. An 
H&E stained section was evaluated for the presence of 
prostate cancer and used for assessment of MYC gene 
amplification by FISH and DAKO dual-color CISH. 
Fluorescence In Situ Hybridization 
The FISH analyzes for MYC-C were performed using 
FISH probes for C-MYC, respectively (DAKO) in 
combination with the Histology FISH Accessory kit 
(DAKO) (Code K5599). The FISH analyses for MYC-C 
were performed using the FISH (DAKO) assays. All 
staining were performed according to the respective 
package insert and subsequently evaluated using a 
fluorescence microscope. The slides that were analyzed 
using the dual-color CISH kit followed the same 
protocols but were not mounted.  
 
Chromogenic In Situ Hybridization 
The dual-color CISH (Code SK 108) assay contains 
reagents required to complete a 2-step 
immunohistochemical staining procedure to detect 
DAKO Texas red– and FITC-labeled FISH probes. 
First, the aforementioned FISH procedures were 
followed, except the last dehydration and mounting 
step was omitted and the tissue specimens for CISH 
analysis were immersed in the CISH Wash Buffer 
(DAKO). The next step in the CISH procedure is to 
block the tissue specimens for endogen peroxidase with 
a ready-to-use Peroxidase Blocker (DAKO). 
Peroxidase blocking is followed by incubation with a 
ready- to- use CISH Antibody Mix (DAKO), which 
comprises a mixture of anti-FITC conjugated with 
horseradish peroxidase and anti–Texas red conjugated 
with alkaline phosphatase. Tissue specimens were then 
incubated with a red chromogen followed by 
incubation with a blue chromogen [6]. Finally, the 
specimens were counterstained with hematoxylin 
(DAKO Hematoxylin - Code S3301) and coverslipped 
(Tissue-Mount, Aquatex de Merck), and the results 
were evaluated using a bright-field microscope. 
Interpretation of Staining 
Samples were scored according to the guidelines 
provided with the FISH probe used with the DAKO 
DuoCISH kit. However, the CISH signals are slightly 
larger than the corresponding FISH signals. For all 
tumor specimens in this study signals from 20 nuclei 
were counted.  
RESULTS 
In the forty patients studied, the average age was 63 
years, with a median of 63.5 years, the youngest was 51 
years and the largest 73. Twelve patients showed 
amplification of C-MYC gene, showing a prevalence of 
30% of the sample. 
The dual-color CISH assay was tested with MYC-C 
probe. This was qualitative, evaluating the general 
appearance of CISH staining with respect to tissue 
morphologic features and the balance between red and 
blue signal size, sharpness, and intensity. For the probe, 
the general appearance seemed almost identical 
between the 2 methods (Figure 1). 
 
Figure 1. Dot-to-dot conversion of FISHsignals to CISH 
signals. 
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DISCUSSION 
The present study showed that the dual-color CISH 
assay can convert Texas red and FITC FISH signals 
into chromogenic signals in context with preserved 
morphologic features. A number of previously 
published studies with HER2 probes have likewise 
shown high concordance between FISH and CISH 
assays, in the range of 91% to 100%, which seems to 
confirm the reliability of CISH [9-12]. 
The MYC-C sensitizes cells to a wide range of 
proapoptotic stimuli. During apoptosis, MYC-C induces 
the release of cytochrome c from mitochondria into the 
cytosol, possibly through the activation of pro-
apoptotic molecule BAX. Similarly, other authors 
sought this type of alterations in prostate cancer. [13-
15]. Pflueger et al [16], where they have identified 
NDRG1-ERG fusion in prostate tumors in 44% of 
patients (n = 100) who received radical prostatectomy, 
also considering patients with advanced disease. This 
identification of NDRG1-ERG fusion results in the 
formation of chimeric proteins in prostate cancer and 
has potential clinical and biological implications. The 
NDRG1 is involved in cell differentiation, suppressed 
by the oncogenes N-MYC and C-MYC and therefore 
often deregulated in cancer cells. It is expected that the 
testing of dual-color CISH in a relatively short time, is 
an accepted method in the routine evaluation of 
diagnosis of the situation in the different types of 
cancer. Using a light microscope instead of a 
fluorescence microscope and the ability to easily 
observe the morphological characteristics of the fund 
will be seen as advantages over current FISH assays. 
Based on data from different studies [6, 17, 18], our 
experience using the technique of CISH [19-23] and the 
results of this study, the dual-color DAKO CISH assay 
appears to be sensitive and specific, and because of his 
familiarity with immunohistochemical analysis, which 
may have the potential to be the most used in pathology 
laboratories in the future. 
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